Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

M. Lyadova

View on Semantic Scholar

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Induction chemo-immunotherapy followed by surgery or radiotherapy for locally-advanced III stage non-small cell lung cancer: prospective single center non-randomized study (preliminary results)

Background. The evolving modalities of systemic treatment for non-small cell lung cancer (NSCLC) promotes the need to redefine different strategies for combined treatment in stage III and borderline-resectable lung cancer. Hereby we present the outcomes of a neoadjuvant chemo-immunotherapy regimen with subsequent in...

Y. Esakov, O. A. Kuchevskaya, I. Pokataev et al. · 0 citations
Open access Sep 2026

Efficacy and safety profile of dMMR/MSI immunotherapy in metastatic colorectal cancer in real-world clinical practice

Introduction. Deficiency of the mismatch repair system (dMMR) and microsatellite instability (MSI) occur in only 4–5% of patients with metastatic colorectal cancer (mCRC), but this molecular subgroup is characterized by high sensitivity to immune checkpoint inhibitors. Data on the efficacy and safety of such thera...

M. Lyadova, O. N. Zauzolkov, Julia S. Mansurova et al. · 0 citations
Open access Sep 2026

Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing

The frequency and distribution of common, clinically relevant, and rare DPYD variants in a Russian cohort of patients receiving fluoropyrimidine-containing chemotherapy and the observed allele frequencies with European and East Asian reference populations are compared.

D. Fedorinov, V. Lyadov, M. Lyadova et al. · 0 citations
Open access Jul 2026

Effectiveness of first-line therapy for metastatic small-cell lung cancer: real-world data

The combination of atezolizumab with platinum-based chemotherapy and etoposide as a first-line treatment for SCLC demonstrates high efficacy and an acceptable safety profile in real-world clinical settings.

Julia S. Mansurova, M. Lyadova, E. A. Denisova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.